WO2009108551A3 - Heteroaryl amide analogues - Google Patents
Heteroaryl amide analogues Download PDFInfo
- Publication number
- WO2009108551A3 WO2009108551A3 PCT/US2009/034379 US2009034379W WO2009108551A3 WO 2009108551 A3 WO2009108551 A3 WO 2009108551A3 US 2009034379 W US2009034379 W US 2009034379W WO 2009108551 A3 WO2009108551 A3 WO 2009108551A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heteroaryl amide
- disorder
- amide analogues
- analogues
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
Compounds, pharmaceutical compositions, and methods of use are disclosed for heteroaryl amide analogues of formula Ia and/or Ib. In certain embodiments, the heteroaryl amide analogues are agonists and/or ligands of dopamine receptors and may be useful, inter alia, for the treatment of a condition responsive to P2X7 receptor modulation, for example, pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3108208P | 2008-02-25 | 2008-02-25 | |
US61/031,082 | 2008-02-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009108551A2 WO2009108551A2 (en) | 2009-09-03 |
WO2009108551A3 true WO2009108551A3 (en) | 2009-11-26 |
Family
ID=41016676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/034379 WO2009108551A2 (en) | 2008-02-25 | 2009-02-18 | Heteroaryl amide analogues |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009108551A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2012136451A (en) | 2010-01-28 | 2014-03-10 | Президент Энд Феллоуз Оф Гарвард Колледж | COMPOSITIONS AND METHODS FOR IMPROVING PROTEASOMIC ACTIVITY |
GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
PL2707101T3 (en) | 2011-05-12 | 2019-10-31 | Proteostasis Therapeutics Inc | Proteostasis regulators |
WO2013014587A1 (en) | 2011-07-22 | 2013-01-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
US9150574B2 (en) | 2011-09-14 | 2015-10-06 | Proximagen Limited | Enzyme inhibitor compounds |
GB201115853D0 (en) * | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
TWI576347B (en) | 2012-01-20 | 2017-04-01 | 艾克泰聯製藥有限公司 | Heterocyclic amide derivatives as p2x7 receptor antagonists |
JOP20130213B1 (en) * | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | 5-ht3 receptor antagonists |
SG11201504369SA (en) * | 2012-12-12 | 2015-07-30 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
KR102232744B1 (en) * | 2012-12-18 | 2021-03-26 | 이도르시아 파마슈티컬스 리미티드 | Indole carboxamide derivatives as p2x7 receptor antagonists |
KR102220847B1 (en) | 2013-01-22 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | Heterocyclic amide derivatives as p2x7 receptor antagonists |
EP2956135B1 (en) * | 2013-01-22 | 2016-11-16 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as p2x7 receptor antagonists |
US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
ES2638850T3 (en) | 2013-02-19 | 2017-10-24 | Pfizer Inc. | Azabenzimidazole compounds as inhibitors of PDE4 isoenzymes for the treatment of CNS disorders and other disorders |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
EP2905282A1 (en) | 2014-02-05 | 2015-08-12 | AXXAM S.p.A. | Substituted thiazole or oxazole as P2X7 receptor antagonists |
WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
SG11201700243YA (en) | 2014-08-06 | 2017-02-27 | Pfizer | Imidazopyridazine compounds |
CN106795172B (en) | 2014-09-29 | 2020-07-28 | 武田药品工业株式会社 | Crystalline forms of 1- (1-methyl-1H-pyrazol-4-yl) -N- ((1R,5S,7S) -9-methyl-3-oxa-9-azabicyclo [3.3.1] non-7-yl) -1H-indole-3-carboxamide |
EP3233841A1 (en) * | 2014-12-15 | 2017-10-25 | Merck Patent GmbH | Indole and azaindoles derivatives and their use in neurodegenerative diseases |
HUE055662T2 (en) | 2014-12-29 | 2021-12-28 | Us Health | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
US9708359B2 (en) | 2015-08-06 | 2017-07-18 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof |
CA3010615C (en) | 2016-01-14 | 2024-02-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
EP3290417A1 (en) | 2016-08-31 | 2018-03-07 | AXXAM S.p.A. | 2-chloro-n-[2-(1,3-thiazol-5-yl)ethyl]-5-(5-fluoropyrimidin-2-yl)-benzamides and their use as p2x7 receptor antagonists |
EP3290416A1 (en) | 2016-08-31 | 2018-03-07 | AXXAM S.p.A. | Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives and their use as p2x7 receptor antagonist |
TW201819361A (en) | 2016-09-03 | 2018-06-01 | 印度商托仁特生技有限公司 | Novel indazole compounds |
EP3398941A1 (en) | 2017-05-03 | 2018-11-07 | AXXAM S.p.A. | Heterocyclic p2x7 antagonists |
US11111264B2 (en) | 2017-09-21 | 2021-09-07 | Chimerix, Inc. | Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof |
EP4015039A1 (en) | 2020-12-18 | 2022-06-22 | AXXAM S.p.A. | Heterocyclic derivatives as p2x7 receptor antagonists |
WO2023031319A1 (en) | 2021-09-03 | 2023-03-09 | Axxam S.P.A. | 2,4-dihydro-3h-1,2,4-triazol-3-one p2x7 antagonists |
CA3230066A1 (en) * | 2021-09-03 | 2023-03-09 | Xiaoqiang Xu | Indole compound, and preparation method therefor and use thereof |
WO2023198199A1 (en) * | 2022-04-15 | 2023-10-19 | 先声再明医药有限公司 | Myt1 kinase inhibitor |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004018461A2 (en) * | 2002-08-23 | 2004-03-04 | Pharmacia & Upjohn Company Llc | Antibacterial benzoic acid derivatives |
US6812226B2 (en) * | 1999-12-17 | 2004-11-02 | Astrazeneca Ab | P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular disease |
US6927219B2 (en) * | 2001-11-12 | 2005-08-09 | Pfizer Inc. | N-alkyl-adamantyl triazinyl benzamide derivatives |
US20060293337A1 (en) * | 2003-06-02 | 2006-12-28 | Richard Evans | P2x7 receptor antagonists and their use |
WO2007088277A1 (en) * | 2006-02-03 | 2007-08-09 | Sanofi-Aventis | Tricyclic ν-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use |
US20070203209A1 (en) * | 2005-08-18 | 2007-08-30 | Wilmin Bartolini | Useful indole compounds |
US20080027092A1 (en) * | 2003-11-26 | 2008-01-31 | Roger Victor Bonnert | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders |
-
2009
- 2009-02-18 WO PCT/US2009/034379 patent/WO2009108551A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812226B2 (en) * | 1999-12-17 | 2004-11-02 | Astrazeneca Ab | P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular disease |
US6927219B2 (en) * | 2001-11-12 | 2005-08-09 | Pfizer Inc. | N-alkyl-adamantyl triazinyl benzamide derivatives |
WO2004018461A2 (en) * | 2002-08-23 | 2004-03-04 | Pharmacia & Upjohn Company Llc | Antibacterial benzoic acid derivatives |
US20060293337A1 (en) * | 2003-06-02 | 2006-12-28 | Richard Evans | P2x7 receptor antagonists and their use |
US20080027092A1 (en) * | 2003-11-26 | 2008-01-31 | Roger Victor Bonnert | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders |
US20070203209A1 (en) * | 2005-08-18 | 2007-08-30 | Wilmin Bartolini | Useful indole compounds |
WO2007088277A1 (en) * | 2006-02-03 | 2007-08-09 | Sanofi-Aventis | Tricyclic ν-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use |
Also Published As
Publication number | Publication date |
---|---|
WO2009108551A2 (en) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009108551A3 (en) | Heteroaryl amide analogues | |
UA99729C2 (en) | Heteroaryl amide analogues | |
WO2012021629A3 (en) | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | |
EP2119476A3 (en) | Amide derivatives as positive allosteric modulators and methods of use thereof | |
WO2010057118A3 (en) | Heterocyclic antagonists of prostaglandin d2 receptors | |
UA104869C2 (en) | Normal;heading 1;heading 2;heading 3;PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | |
WO2010039977A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
WO2008064353A3 (en) | 7,8-saturated-4,5-epoxy-morphinanium analogs | |
WO2007067616A3 (en) | Uses of myostatin antagonists | |
WO2008152099A3 (en) | Aryl/hetarylamides as modulators of the ep2 receptor | |
EP4268814A3 (en) | Pharmaceutical composition for the treatment of dry eye | |
WO2010148007A3 (en) | Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof | |
WO2010077882A3 (en) | Antagonists of lysophosphatidic acid receptors | |
WO2008140507A8 (en) | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | |
WO2009100294A3 (en) | Amide derivatives as positive allosteric modulators and methods of use thereof | |
WO2007148208A3 (en) | Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands | |
WO2010008831A3 (en) | Compounds and methods for modulating g protein-coupled receptors | |
WO2008021851A3 (en) | Novel compounds as antagonists or inverse agonists for opioid receptors | |
IL207001A0 (en) | Parenteral formulations for the administration of dopamine agonists | |
WO2008121348A3 (en) | Peripheral opioid receptor antagonists and uses thereof | |
WO2008132600A3 (en) | Trpv1 antagonists and uses thereof | |
WO2010068775A3 (en) | Alkyne antagonists of lysophosphatidic acid receptors | |
WO2009117150A3 (en) | Method of treating lupus with ceramide derivatives | |
EP2019646A4 (en) | Method, device, and system for delivery of therapeutic agents to the eye | |
SI2024368T1 (en) | 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09715672 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09715672 Country of ref document: EP Kind code of ref document: A2 |